Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
about
Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple TherapyMultiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats.
P2860
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
@en
type
label
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
@en
prefLabel
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
@en
P2093
P2860
P1476
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
@en
P2093
Francois-Ludovic Sauvage
Francoise Stanke-Labesque
Gerard Babany
Jean-Francois Jourdil
Marie-Claude Gagnieu
P2860
P304
P356
10.1097/FTD.0B013E3181A665E3
P577
2009-06-01T00:00:00Z